Skip to main content
. Author manuscript; available in PMC: 2014 Oct 15.
Published in final edited form as: Nutr Cancer. 2013 Oct 15;65(8):1232–1244. doi: 10.1080/01635581.2013.832779

Figure 4. Embelin and ellagic acid inhibit NF-kB and STAT3 pathways.

Figure 4

(A–C) MIA PaCa-2 cells were cultured for 72h in the presence of indicated doses of embelin or ellagic acid or Jak inhibitor AG490 (50 μM). (A) NFκB binding activity was measured by dual luciferase reporter assay (Promega). (D) Proliferation was assessed by measuring 3H-thymidine incorporation into DNA. (D, E) Cells were transfected with survivin or control siRNA using the electroporation Amaxa System Nucleofector. P-values in A and D are for one-sided one-sample t-tests comparing with 1 (controls). P* is the p-value for testing the synergistic effect (defined similar to Fig. 3). With Bonferroni’s adjustment, p<0.0125 are considered as significant.